Adjuvant immunotherapy and targeted therapy for liver cancer with portal vein tumor thrombus
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving two medicines (an immunotherapy and a targeted therapy) after surgery can help prevent liver cancer from coming back in people with a specific type of tumor clot in the liver's main vein. If you've had surgery to remove the cancer and meet the health criteria, this treatment may lower your risk of recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of liver cancer called hepatocellular carcinoma (HCC) that was confirmed by biopsy or after surgery.
- You had surgery to remove the cancer and at least 4 weeks have passed since the surgery.
- A tumor clot (thrombus) was found in the main vein of your liver (portal vein) during or after surgery.
- You are between 18 and 75 years old, and you are in generally good health (able to do your daily activities).
- You have not had any prior treatment for this liver cancer, like chemotherapy or radiation, before your surgery.
- Your cancer has not spread beyond the liver, and you do not have serious other health conditions like autoimmune disease or poorly controlled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving an immunotherapy drug (sintilimab) after surgery helps keep liver cancer with microscopic blood vessel invasion from coming back. It may improve chances of staying cancer-free after surgery.
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a combination of treatments for liver cancer that has spread to the main portal vein. It uses a special stent, radiation seeds, and targeted therapies to shrink the tumor and improve blood flow. This may help patients who haven't had certain prior treatments.
This trial tests whether adding immunotherapy (atezolizumab/bevacizumab) and a type of internal radiation (I-125 seeds) to standard chemoembolization (TACE) can help people with liver cancer that has spread into the main liver blood vessel (portal vein). It aims to control the tumor and improve outcomes.
This trial combines a procedure called TIPS (which helps relieve pressure in the liver) with two drugs—lenvatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—for people with advanced liver cancer that has spread into the main vein of the liver. It aims to see if this combination can help control the cancer and improve symptoms.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.